{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:00:07Z","timestamp":1792598407897,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.tem.2013.12.006","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T15:34:02Z","timestamp":1389368042000},"page":"197-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Glucocorticoids and bone: local effects and systemic implications"],"prefix":"10.1016","volume":"25","author":[{"given":"Holger","family":"Henneicke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia J.","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara C.","family":"Brennan-Speranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2013.12.006_bib0005","first-page":"137","article-title":"The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism)","volume":"50","author":"Cushing","year":"1932","journal-title":"Bull. Johns Hopkins Hosp."},{"key":"10.1016\/j.tem.2013.12.006_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(24)00526-3","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis","volume":"24","author":"Hench","year":"1949","journal-title":"Proc. Staff Meet. Mayo Clin."},{"key":"10.1016\/j.tem.2013.12.006_bib0015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0020","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.tem.2013.12.006_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1758-5996-5-18","article-title":"Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients","volume":"5","author":"Gonzalez-Gonzalez","year":"2013","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.tem.2013.12.006_bib0030","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJM199906243402502","article-title":"Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group","volume":"340","author":"Niewoehner","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.tem.2013.12.006_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000048130","article-title":"Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration","volume":"56","author":"Kanda","year":"2001","journal-title":"Horm. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00198-005-1923-3","article-title":"High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass","volume":"17","author":"Natsui","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0045","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2013.5023","article-title":"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial","volume":"309","author":"Leuppi","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.tem.2013.12.006_bib0050","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(11)60607-7","article-title":"Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"Meijvis","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tem.2013.12.006_bib0055","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1525-1497.2002.10649.x","article-title":"Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly","volume":"17","author":"Blackburn","year":"2002","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2265.2011.04242.x","volume":"77","author":"Yuen","year":"2012","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2013.12.006_bib0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.tem.2013.12.006_bib0070","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1073\/pnas.0711119105","article-title":"Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice","volume":"105","author":"Ferron","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tem.2013.12.006_bib0075","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1172\/JCI63377","article-title":"Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism","volume":"122","author":"Brennan-Speranza","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2013.12.006_bib0080","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1101\/gad.9.13.1608","article-title":"Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation","volume":"9","author":"Cole","year":"1995","journal-title":"Genes Dev."},{"key":"10.1016\/j.tem.2013.12.006_bib0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","article-title":"Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor","volume":"11","author":"Rauch","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00223-005-0297-z","article-title":"Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling","volume":"79","author":"Sher","year":"2006","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bone.2009.03.673","article-title":"Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice","volume":"45","author":"Kalak","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0100","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1210\/endo-121-6-1985","article-title":"Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro","volume":"121","author":"Bellows","year":"1987","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2013.12.006_bib0105","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1074\/jbc.M702687200","article-title":"Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling","volume":"283","author":"Zhou","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2013.12.006_bib0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1242\/dev.027706","article-title":"Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice","volume":"136","author":"Zhou","year":"2009","journal-title":"Development"},{"key":"10.1016\/j.tem.2013.12.006_bib0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bone.2010.06.002","article-title":"Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation","volume":"47","author":"Yang","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","article-title":"Bone loss in response to long-term glucocorticoid therapy","volume":"8","author":"LoCascio","year":"1990","journal-title":"Bone Miner."},{"key":"10.1016\/j.tem.2013.12.006_bib0125","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.bone.2011.02.005","article-title":"Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis","volume":"48","author":"Kalpakcioglu","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0130","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0135","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1046\/j.1365-2036.2002.01317.x","article-title":"Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease","volume":"16","author":"Stockbrugger","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2013.12.006_bib0140","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tem.2013.12.006_bib0145","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tem.2013.12.006_bib0150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/thx.2011.160028","article-title":"Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies","volume":"66","author":"Loke","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.tem.2013.12.006_bib0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00774-007-0821-5","article-title":"Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study","volume":"26","author":"Kuroki","year":"2008","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0160","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","article-title":"Glucocorticoids and the regulation of growth hormone secretion","volume":"9","author":"Mazziotti","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2013.12.006_bib0170","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1172\/JCI68062","article-title":"Steroids and osteoporosis: the quest for mechanisms","volume":"123","author":"Manolagas","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2013.12.006_bib0175","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","article-title":"Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density","volume":"147","author":"Jia","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2013.12.006_bib0180","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI28084","article-title":"Glucocorticoids suppress bone formation via the osteoclast","volume":"116","author":"Kim","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2013.12.006_bib0185","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","article-title":"Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength","volume":"145","author":"O\u2019Brien","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2013.12.006_bib0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.bone.2011.06.013","article-title":"Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism","volume":"49","author":"Henneicke","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0195","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1474-9726.2009.00545.x","article-title":"Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice","volume":"9","author":"Weinstein","year":"2010","journal-title":"Aging Cell"},{"key":"10.1016\/j.tem.2013.12.006_bib0200","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2013.12.006_bib0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-11-0751","article-title":"Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals","volume":"166","author":"Kauh","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2013.12.006_bib0210","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s00223-009-9303-1","article-title":"Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells","volume":"85","author":"Mak","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0215","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.lfs.2009.09.009","article-title":"Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss","volume":"85","author":"Wang","year":"2009","journal-title":"Life Sci."},{"key":"10.1016\/j.tem.2013.12.006_bib0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2008.12.035","article-title":"BMP\/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis","volume":"379","author":"Hayashi","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tem.2013.12.006_bib0225","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/art.23454","article-title":"Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice","volume":"58","author":"Yao","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tem.2013.12.006_bib0230","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1096\/fj.10-173393","article-title":"An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation","volume":"25","author":"Rauch","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.tem.2013.12.006_bib0235","doi-asserted-by":"crossref","first-page":"49011","DOI":"10.1074\/jbc.M207804200","article-title":"Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice","volume":"277","author":"Takeuchi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2013.12.006_bib0240","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1507\/endocrj.EJ11-0219","article-title":"Regulation of osteoblast differentiation by interleukin-11 via AP-1 and Smad signaling","volume":"59","author":"Matsumoto","year":"2012","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2013.12.006_bib0245","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molmed.2012.04.005","article-title":"Glucocorticoid receptor signaling in bone cells","volume":"18","author":"Moutsatsou","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0250","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tox.2009.01.016","article-title":"Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts","volume":"258","author":"Chang","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.tem.2013.12.006_bib0255","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1210\/me.2007-0153","article-title":"Mitogen-activated protein kinase phosphatase 1\/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation","volume":"21","author":"Horsch","year":"2007","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tem.2013.12.006_bib0260","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/jcp.22412","article-title":"Developmentally regulated inhibition of cell cycle progression by glucocorticoids through repression of cyclin A transcription in primary osteoblast cultures","volume":"226","author":"Gabet","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tem.2013.12.006_bib0265","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcp.21335","article-title":"Regulation of bim in glucocorticoid-mediated osteoblast apoptosis","volume":"215","author":"Espina","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tem.2013.12.006_bib0270","doi-asserted-by":"crossref","first-page":"e37030","DOI":"10.1371\/journal.pone.0037030","article-title":"Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tem.2013.12.006_bib0275","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1042\/CBI20100731","article-title":"Effect of dexamethasone on human osteoblasts in culture: involvement of beta1 integrin and integrin-linked kinase","volume":"35","author":"Naves","year":"2011","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0280","doi-asserted-by":"crossref","first-page":"44326","DOI":"10.1074\/jbc.M111.283481","article-title":"Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts","volume":"286","author":"Almeida","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2013.12.006_bib0285","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1242\/jcs.063032","article-title":"Bone remodelling at a glance","volume":"124","author":"Crockett","year":"2011","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.tem.2013.12.006_bib0290","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1749-6632.2009.05243.x","article-title":"Osteocyte primary cilium and its role in bone mechanotransduction","volume":"1192","author":"Temiyasathit","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tem.2013.12.006_bib0295","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1210\/en.2009-1488","article-title":"Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice","volume":"151","author":"Weinstein","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2013.12.006_bib0300","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/jbmr.160","article-title":"Glucocorticoid-induced autophagy in osteocytes","volume":"25","author":"Xia","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0305","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1096\/fj.11-182519","article-title":"Glucocorticoid dose determines osteocyte cell fate","volume":"25","author":"Jia","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.tem.2013.12.006_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.22660","article-title":"Antagonistic interplay between mechanical forces and glucocorticoids in bone: a tale of kinases","volume":"111","author":"Bellido","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tem.2013.12.006_bib0315","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1210\/jc.2004-0164","article-title":"Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis","volume":"89","author":"Dovio","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0320","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1359\/JBMR.041233","article-title":"Influence of glucocorticoids on human osteoclast generation and activity","volume":"20","author":"Sivagurunathan","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0325","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2013.12.006_bib0330","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2220\/biomedres.32.37","article-title":"Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression","volume":"32","author":"Goto","year":"2011","journal-title":"Biomed. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0335","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0340","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0345","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/jbmr.1941","article-title":"RANKL subcellular trafficking and regulatory mechanisms in osteocytes","volume":"28","author":"Honma","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0350","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bone.2012.01.025","article-title":"Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations","volume":"50","author":"Kennedy","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0355","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1359\/jbmr.080207","article-title":"Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction","volume":"23","author":"Kogianni","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0360","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1196\/annals.1402.057","article-title":"Glucocorticoids and the osteoclast","volume":"1116","author":"Kim","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tem.2013.12.006_bib0365","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0370","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2012.04.017","article-title":"The link between stress and feeding behaviour","volume":"63","author":"Maniam","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tem.2013.12.006_bib0375","first-page":"97","article-title":"Biochemical markers of bone turnover. Part I: biochemistry and variability","volume":"26","author":"Seibel","year":"2005","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.tem.2013.12.006_bib0380","first-page":"123","article-title":"Biochemical markers of bone turnover. Part II: clinical applications in the management of osteoporosis","volume":"27","author":"Seibel","year":"2006","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.tem.2013.12.006_bib0385","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/382448a0","article-title":"Increased bone formation in osteocalcin-deficient mice","volume":"382","author":"Ducy","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.tem.2013.12.006_bib0390","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bone.2011.04.017","article-title":"Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice","volume":"50","author":"Ferron","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0395","first-page":"1497","article-title":"Bone loss and turnover after cardiac transplantation","volume":"82","author":"Shane","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0400","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/jbmr.5650060815","article-title":"Nonhypercalcemic 1,25-(OH)2D3 analogs potently induce the human osteocalcin gene promoter stably transfected into rat osteosarcoma cells (ROSCO-2)","volume":"6","author":"Morrison","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/jc.2008-1455","article-title":"Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus","volume":"94","author":"Kanazawa","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0410","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1359\/jbmr.081234","article-title":"Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men","volume":"24","author":"Kindblom","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0415","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1530\/EJE-09-0585","article-title":"Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals","volume":"161","author":"Zhou","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2013.12.006_bib0420","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2265.2011.04035.x","article-title":"Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance","volume":"75","author":"Iglesias","year":"2011","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2013.12.006_bib0425","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00198-010-1322-2","article-title":"Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus","volume":"22","author":"Strapazzon","year":"2011","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0430","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1210\/jc.2008-0270","article-title":"The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training","volume":"94","author":"Fernandez-Real","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0435","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2008-1422","article-title":"Association between serum osteocalcin and markers of metabolic phenotype","volume":"94","author":"Pittas","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0440","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ijo.2009.282","article-title":"A new link between skeleton, obesity and insulin resistance: relationships between osteocalcin, leptin and insulin resistance in obese children before and after weight loss","volume":"34","author":"Reinehr","year":"2010","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.tem.2013.12.006_bib0445","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/ATVBAHA.110.204859","article-title":"Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome","volume":"30","author":"Saleem","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.tem.2013.12.006_bib0450","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00198-011-1600-7","article-title":"Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study","volume":"23","author":"Iki","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tem.2013.12.006_bib0455","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/dmrr.1045","article-title":"The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects","volume":"25","author":"Hwang","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.tem.2013.12.006_bib0460","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/oby.2012.108","article-title":"Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults","volume":"20","author":"Polgreen","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.tem.2013.12.006_bib0465","doi-asserted-by":"crossref","first-page":"E1982","DOI":"10.1210\/jc.2011-0587","article-title":"Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1\u201384) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study)","volume":"96","author":"Schafer","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0470","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/jbmr.1865","article-title":"Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials","volume":"28","author":"Schwartz","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0475","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tem.2013.12.006_bib0480","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bone.2009.12.032","article-title":"Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate","volume":"46","author":"Burshell","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0485","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1172\/JCI66180","article-title":"New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it","volume":"122","author":"Ferris","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2013.12.006_bib0490","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1172\/JCI65952","article-title":"Osteocalcin regulates murine and human fertility through a pancreas\u2013bone\u2013testis axis","volume":"123","author":"Oury","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2013.12.006_bib0495","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.cell.2011.02.004","article-title":"Endocrine regulation of male fertility by the skeleton","volume":"144","author":"Oury","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tem.2013.12.006_bib0500","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cell.2013.08.042","article-title":"Maternal and offspring pools of osteocalcin influence brain development and functions","volume":"155","author":"Oury","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.tem.2013.12.006_bib0505","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/qjmed\/hci029","article-title":"A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids","volume":"98","author":"van Staa","year":"2005","journal-title":"QJM"},{"key":"10.1016\/j.tem.2013.12.006_bib0510","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.tem.2013.12.006_bib0515","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0520","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jbmr.362","article-title":"Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"26","author":"Hansen","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0525","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0530","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","article-title":"Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis","volume":"355","author":"de Nijs","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0535","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2013.12.006_bib0540","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1074\/jbc.M412817200","article-title":"Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation","volume":"280","author":"Plotkin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2013.12.006_bib0545","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0550","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2010-2552","article-title":"The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1","volume":"96","author":"Gatti","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0555","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2265.2009.03728.x","article-title":"The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis","volume":"72","author":"Anastasilakis","year":"2010","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2013.12.006_bib0560","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1359\/jbmr.070328","article-title":"Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells","volume":"22","author":"Datta","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0565","doi-asserted-by":"crossref","first-page":"9787","DOI":"10.1074\/jbc.M110.179127","article-title":"Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein\u2013Runx2 pathway","volume":"286","author":"Hisa","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2013.12.006_bib0570","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0575","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial","volume":"28","author":"Gluer","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0580","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0585","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0590","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0595","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0600","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","article-title":"Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates","volume":"69","author":"Dore","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tem.2013.12.006_bib0605","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","article-title":"Involvement of WNT\/beta-catenin signaling in the treatment of osteoporosis","volume":"93","author":"Rossini","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0610","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/jbmr.1753","article-title":"Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets?","volume":"27","author":"Cooper","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0615","first-page":"S13","article-title":"Pharmacodynamics of glucocorticoids","volume":"29","author":"Strehl","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.tem.2013.12.006_bib0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-07-0606","article-title":"Mechanisms of glucocorticoid-induced myopathy","volume":"197","author":"Schakman","year":"2008","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.tem.2013.12.006_bib0625","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbspin.2010.02.025","article-title":"Glucocorticoid-induced myopathy","volume":"78","author":"Pereira","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.tem.2013.12.006_bib0630","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","article-title":"The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis","volume":"79","author":"van Staa","year":"2006","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0635","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/eje.1.01841","article-title":"Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects","volume":"152","author":"Bonadonna","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2013.12.006_bib0640","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrendo.2012.89","article-title":"Bone: the conundrum of glucocorticoid-induced osteoporosis","volume":"8","author":"Teitelbaum","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2013.12.006_bib0645","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1152\/physrev.1989.69.3.990","article-title":"Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone","volume":"69","author":"Hauschka","year":"1989","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tem.2013.12.006_bib0650","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/03008208909049995","article-title":"Gla-containing proteins of bone","volume":"21","author":"Price","year":"1989","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0655","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bone.2011.04.017","article-title":"Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice","volume":"50","author":"Ferron","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0660","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cell.2010.06.003","article-title":"Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism","volume":"142","author":"Ferron","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.tem.2013.12.006_bib0665","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00223-012-9630-5","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"91","author":"Rizzoli","year":"2012","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0670","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJM199306173282404","article-title":"Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin","volume":"328","author":"Sambrook","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0675","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","article-title":"Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial","volume":"125","author":"Buckley","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0680","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E","article-title":"The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach","volume":"42","author":"Amin","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tem.2013.12.006_bib0685","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tem.2013.12.006_bib0690","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3899\/jrheum.081207","article-title":"Once-weekly oral alendronate 70mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial","volume":"36","author":"Stoch","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.tem.2013.12.006_bib0695","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002960000080","article-title":"Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids","volume":"20","author":"Yilmaz","year":"2001","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0700","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tem.2013.12.006_bib0705","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s001980070122","article-title":"Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients","volume":"11","author":"Eastell","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0710","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","article-title":"Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy","volume":"69","author":"Reid","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0715","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2013.12.006_bib0720","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tem.2013.12.006_bib0725","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.tem.2013.12.006_bib0730","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3899\/jrheum.110947","article-title":"Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study","volume":"39","author":"Karras","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.tem.2013.12.006_bib0735","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis","volume":"337","author":"Adachi","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0740","first-page":"214","article-title":"Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study","volume":"66","author":"Cortet","year":"1999","journal-title":"Rev. Rhum. Engl. Ed."},{"key":"10.1016\/j.tem.2013.12.006_bib0745","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jcem.83.4.4742","article-title":"Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group","volume":"83","author":"Roux","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2013.12.006_bib0750","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-9343(99)80154-5","article-title":"Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis","volume":"99","author":"Struys","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tem.2013.12.006_bib0755","doi-asserted-by":"crossref","first-page":"e8202","DOI":"10.1371\/journal.pone.0008202","article-title":"Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis","volume":"4","author":"Wust","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tem.2013.12.006_bib0760","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1210\/en.2012-2221","article-title":"Effects of the selective glucocorticoid receptor modulator compound A on bone metabolism and inflammation in male mice with collagen-induced arthritis","volume":"154","author":"Rauner","year":"2013","journal-title":"Endocrinology"}],"container-title":["Trends in Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276013002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276013002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T13:48:27Z","timestamp":1746107307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276013002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1043276013002142"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2013.12.006","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocorticoids and bone: local effects and systemic implications","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2013.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}